Delivery Order SPE2DB22D1017-SPE2DB25FH0EH
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Vemlidy 25 mg tablets (30-count units) with a ceiling value of $7,213.88. This firm fixed-price delivery order, which is not set-aside, represents a single transaction under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 billion through December 2026. The vendor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30 units, valued at $4,584.29. This is a firm fixed-price delivery order with an ultimate completion date of August 19, 2025, issued under a competitive procurement with no set-aside designation. The order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $10,710.30 for Vemlidy 25 mg tablets (30-count units) on July 24, 2025, with an ultimate completion date of July 25, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction within AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency awarded a delivery order valued at $134,109.38 to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract calls for performance at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, with an...
- The Defense Logistics Agency awarded a delivery order valued at $4,700.52 to AmerisourceBergen Drug Corp for Vemlidy 25 mg tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract for pharmaceutical supply to support federal medical procurement needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Vemlidy 25 mg tablets in a quantity of 30 units, with a ceiling value of $10,849.10 and a firm fixed price. This is a non-set-aside competitive award with an ultimate completion date of July 31, 2025. The contract is performed at AmerisourceBergen Drug Corp's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30 units, with a firm fixed price of $9,521.05 and an ultimate completion date of August 19, 2025. This is a non-set-aside, competitively awarded contract with performance to be fulfilled at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a $3,914.21 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Vemlidy 25 mg tablets (30-count units) on July 28, 2025, with an ultimate completion date of July 29, 2025. This is a non-set-aside competitive award representing a child order under AmerisourceBergen's larger contract vehicle with DLA. Vemlidy is an antiviral medication, and this delivery order reflects AmerisourceBergen's role as a critical pharmaceutical supplier supporting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vemlidy 25 mg tablets in quantities of 30 units, with a ceiling value of $3,176.22 and a completion date of July 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is executed as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global...
- The Defense Logistics Agency awarded a $1,252.42 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vemlidy 25 mg tablets (30-count units). This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The contract involves no set-aside designation and is scheduled for completion by July 25, 2025,...
- SPE2DB22D1017Indefinite Delivery Contract
- SPE2DB22D1017-SPE2DB25FH0EHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,828.40 to AmerisourceBergen Drug Corp for 30 tablets of Vemlidy 25 mg on August 19, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, non-set-aside delivery order performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a pharmaceutical supply delivery under a broader contract vehicle supporting federal medical procurement needs. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00 prime contract vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs globally. As a major pharmaceutical distributor, AmerisourceBergen Drug Corp serves as a critical vendor for the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The company consistently receives competitive awards for both brand-name and generic medications across multiple therapeutic domains, demonstrating its capability to meet federal medical supply requirements through the DLA's Medical Supply Chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 8/19/25 |